Study of trastuzumab deruxtecan for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer that cannot be removed by surgery or has spread to other parts of the body.
- You are 18 years or older.
- Your cancer is HER2-positive, meaning it has a certain protein that helps it grow.
- You have had at least one prior cancer treatment as prescribed by your doctor.
- You are about to start or have recently started trastuzumab deruxtecan (within the last 21 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if trastuzumab deruxtecan, a targeted drug, can help people with HER2-positive stomach or gastroesophageal junction cancer who still have cancer cells detected after surgery and chemotherapy. It aims to prevent the cancer from coming back.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This study looks at how safe and effective the drug T-DXd (trastuzumab deruxtecan) is for Chinese patients with a specific type of lung cancer that has a HER2 mutation. It helps understand if this treatment works well in real-world settings.
This study tests a combination of two targeted therapies—trastuzumab deruxtecan and pyrotinib—as a first treatment for HER2-positive breast cancer that has spread. The goal is to see if this combination helps shrink tumors or delay progression better than current options.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
Hear when a new HER2-positive Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.